Skip to main content
Access Resources

MJFF Publications

381 - 390 of 7616 Results
Title
Year
  • Year
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • RESTRICTED
    Title: Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease
    Journal Name: Translational Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40035-023-00374-w
    Citation Count: 7
  • RESTRICTED
    Title: A predictive algorithm to identify ever smoking in medical claims-based epidemiologic studies
    Journal Name: Annals of Epidemiology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.annepidem.2023.04.019
    Best OA location URL:
    Citation Count: 1
  • RESTRICTED
    Title: Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling
    Journal Name: Molecular Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.molcel.2023.08.005
    Citation Count: 5
  • RESTRICTED
    Title: Leucine-rich repeat kinase 2 at a glance
    Journal Name: Journal of Cell Science
    Publisher: The Company of Biologists
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1242/jcs.259724
    Citation Count: 3
  • RESTRICTED
    Title: No laughing white matter: Reduced integrity of the cortical cholinergic pathways in Parkinson's disease-related cognitive impairment
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2023.106243
    Citation Count: 5
  • RESTRICTED
    Title: Novel human pluripotent stem cell-derived hypothalamus organoids demonstrate cellular diversity
    Journal Name: iScience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.isci.2023.107525
    Citation Count: 2
  • RESTRICTED
    Title: Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment
    Journal Name: Patient Preference and Adherence
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.2147/ppa.s420051
    Citation Count: 0
  • RESTRICTED
    Title: Prediction of Parkinson’s disease pathogenic variants using hybrid Machine learning systems and radiomic features
    Journal Name: Physica Medica
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.ejmp.2023.102647
    Best OA location URL:
    Citation Count: 2
  • RESTRICTED
    Title: Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2023.2338
    Citation Count: 5
  • RESTRICTED
    Title: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105511
    Best OA location URL:
    Citation Count: 2
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.